Exelixis Inc

Most Recent

  • uploads///Graph
    Earnings Report

    Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?

    In 2017, Regeneron expects its eye drug, Eylea, to witness single-digit revenue growth on a year-over-year basis. Eylea has continued to be the company’s major revenue driver in the year.

    By Margaret Patrick
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Chimerix Falls 80% following Phase 3 Trial of Brincidofovir

    Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

    By Margaret Patrick
  • uploads///Analysts ratings
    Company & Industry Overviews

    Gilead Sciences on the Street in January: Analyst Recommendations

    In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.

    By Daniel Collins
  • uploads///FI
    Company & Industry Overviews

    What to Expect from Exelixis in 1Q18

    Analysts estimate that in 1Q18, Exelixis will generate revenue of $141.0 million compared to $120.1 million in 4Q17.

    By Daniel Collins
  • uploads///human skeleton _
    Earnings Report

    How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release

    Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

    By Daniel Collins
  • uploads///exe
    Earnings Report

    How Did Exelixis Perform in 1Q18?

    In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion May Boost Cabometyx’s Revenue in 2018

    On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial.

    By Margaret Patrick
  • uploads///Analysts recommendation
    Company & Industry Overviews

    What Amgen’s Analysts Recommend in August 2017

    Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

    By Daniel Collins
  • uploads///AdobeStock_
    Earnings Report

    Exelixis Stock Rises on Revenue Beat

    Yesterday, Exelixis (EXEL) reported its second-quarter results after markets closed. Subsequently, its stock rose 0.99% and closed at $21.48.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    Exelixis Stock Is Up despite Disappointing Clinical Trial Results

    While Exelixis was down 5.9% in after-hours trading after the announcement of disappointing clinical trial results, the stock recovered the losses and closed at $21.14 yesterday, 0.81% higher than its previous close. Based on this price performance, it seems that shareholders had already priced in the trial’s failure.

    By Margaret Patrick
  • uploads///virus _
    Company & Industry Overviews

    Sarepta Therapeutics Stock Rose 96% in 2018

    On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

    By Daniel Collins
  • uploads///medic _
    Company & Industry Overviews

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

    By Daniel Collins
  • uploads///flasks _
    Company & Industry Overviews

    Why Exelixis Stock Soared 46% in November

    Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.

    By Daniel Collins
  • uploads///Cabometyx
    Company & Industry Overviews

    How Exelixis’s Cabozantinib Franchise Is Positioned in November

    In the third quarter, Exelixis’s (EXEL) Cabozantinib franchise generated revenues of $162.9 million, reflecting ~69% YoY growth.

    By Daniel Collins
  • uploads///laboratory _
    Company & Industry Overviews

    Exact Sciences: Why the Stock Price Is Soaring

    On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Gauging Analysts’ Ratings for ArQule Stock in July

    ArQule (ARQL) stock has risen from a low of $5.53 on July 5 to $6.86 on July 6. It closed 20.11% higher at $6.81 on July 6.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Exelixis in July

    On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.

    By Daniel Collins
  • uploads///EXEL
    Company & Industry Overviews

    Understanding Exelixis’s Valuations and Cash Flow Trend

    In Q1 2018, Exelixis (EXEL) generated $71.8 million from operating activities compared to $68.85 million in Q1 2017.

    By Kenneth Smith
  • uploads///EXEL
    Company & Industry Overviews

    Analyzing Exelixis’s Revenue Trend

    Exelixis (EXEL) generated total revenues of $212.34 million in Q1 2018 compared to $80.88 million in Q1 2017.

    By Kenneth Smith
  • uploads///drugs _
    Company & Industry Overviews

    Why Gemphire Therapeutics Stock Is Rising Today

    Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint.

    By Margaret Patrick
  • uploads///headache pain pills medication
    Company & Industry Overviews

    Solid Biosciences’ Stock Price Rose 46.6% on June 19

    On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    BMY Is Rapidly Advancing Its First-Line NSCLC Research Program

    Opdivo has enabled Bristol-Myers Squibb to compete effectively with other melanoma players such as Merck (MRK), Exelixis (EXEL), and Amgen (AMGN).

    By Margaret Patrick
  • uploads///Lenvima
    Company & Industry Overviews

    Levnima Could Be Merck’s Long-Term Growth Driver

    Eisai and Merck are conducting various clinical trials for the label expansion of Lenvima.

    By Daniel Collins
  • uploads///ribbon _
    Company & Industry Overviews

    Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb

    In the first quarter, Bristol-Myers Squibb’s (BMY) Opdivo witnessed sales of ~$1.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume.

    By Margaret Patrick
  • uploads///achievement _
    Company & Industry Overviews

    Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018

    Lenvima is expected to enable Merck to compete effectively with other oncology players such as Exelixis (EXEL) and Pfizer (PFE).

    By Margaret Patrick
  • uploads///FE
    Earnings Report

    How United Therapeutics Performed in 1Q18

    In 1Q18, United Therapeutics (UTHR) generated revenues of $389.2 million compared to $370.5 million in 1Q17.

    By Daniel Collins
  • uploads///Cabometyx
    Company & Industry Overviews

    Cabometyx Could Be Exelixis’s Long-Term Growth Driver

    In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.

    By Daniel Collins
  • uploads///Cabometyx
    Company & Industry Overviews

    How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017

    In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16.

    By Daniel Collins
  • uploads///Spark Therapeutics
    Company & Industry Overviews

    Why Spark Therapeutics Stock Rose in the Week Ended March 29

    On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.

    By Daniel Collins
  • uploads///Sutent
    Company & Industry Overviews

    Pfizer’s Sutent Generated Higher Revenues in 4Q17

    In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for Vertex Pharmaceuticals in January

    Of the 27 analysts covering Vertex Pharmaceuticals in January 2018, ten have recommended a “strong buy,” while 13 have recommended a “buy.”

    By Margaret Patrick
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron

    Dupilumab could be long-term growth driver In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and efficacy of dupilumab for the treatment of individuals with severe steroid-dependent asthma. In the study, at 24 weeks, when […]

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Gauging Exelixis’s High Hopes for Cotellic

    On November 10, 2015, the FDA approved Exelixis’s (EXEL) Cotellic in combination with Roche Holdings’ (RHHBY) Zelboraf (vemurafenib) as a treatment option.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Exelixis’s Label Expansion Collaborations for Cabozantinib

    As a part of the broader lifecycle management for Cabometyx, Exelixis is exploring the drug in combination with other immune checkpoint inhibitors.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Exelixis’s Cabometyx Strategy for 2018

    Exelixis (EXEL) expects the FDA’s approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Reading the Expectations for Exelixis’s Net Profit Margin in 2017

    In 3Q17, Exelixis (EXEL) witnessed the rapid adoption of Cabometyx, mainly driven by the company’s promotional efforts focused on community oncologists.

    By Margaret Patrick
  • uploads///Gleevec
    Company & Industry Overviews

    Behind 4 Key Novartis Money Makers (and Losers) in 3Q17

    In 3Q17, Novartis’s (NVS) Gleevec generated revenues of $445 million, which was ~47% lower YoY (year-over-year) and ~12% lower QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Gilead Sciences on the Street: Analyst Recommendations in October

    Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”

    By Daniel Collins
  • uploads///Cabometyx and Cometriq
    Company & Industry Overviews

    How Is Cabometyx and Cometriq Positioned after 1H17?

    In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16.

    By Daniel Collins
  • uploads///Sandostatin Afinitor and Exjade
    Company & Industry Overviews

    An Update on Novartis’s Sandostatin, Afinitor, and Exjade

    In 1H17, Novartis’s (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Analyst recommendations
    Company & Industry Overviews

    Analyst Recommendations for Regeneron Pharmaceuticals in August

    Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”

    By Daniel Collins
  • uploads///Chart  Opdivo
    Earnings Report

    Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo

    Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Inside Exelixis’s Robust Growth Strategy for Cabometyx

    Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Exelixis’s Tough Competition in Renal Cell Carcinoma

    After the launch of Cabometyx in the US in 2Q16, Exelixis has focused its attention on promoting it to thought leaders and clinicians who have treated many RCC patients.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016

    Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.

    By Margaret Patrick
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Begins the Last Week of 2015 on a Negative Note

    The iShares Nasdaq Biotechnology ETF (IBB) fell by 0.75% on December 28, underperforming the broader market.

    By Peter Neil
  • uploads///
    Earnings Report

    FuelCell Energy’s Outlook and Analysts’ Recommendations

    Among the Wall Street analysts tracking FuelCell Energy, 67% are in the favor of a “buy,” while 33% recommend a “hold” on the stock.

    By Vineet Kulkarni
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.